Teleflex (NYSE:TFX) Rating Increased to Strong-Buy at BMO Capital Markets

BMO Capital Markets upgraded shares of Teleflex (NYSE:TFX) to a strong-buy rating in a research report released on Wednesday morning,Zacks.com reports.

Other analysts have also issued research reports about the stock. Piper Sandler upgraded shares of Teleflex from a “neutral” rating to an “overweight” rating and lifted their price objective for the company from $140.00 to $160.00 in a research note on Monday, June 8th. Royal Bank Of Canada upgraded shares of Teleflex from a “sector perform” rating to an “outperform” rating and raised their price target for the stock from $135.00 to $155.00 in a report on Friday, May 8th. Wall Street Zen raised shares of Teleflex from a “sell” rating to a “hold” rating in a research note on Saturday, June 27th. Weiss Ratings reiterated a “sell (d)” rating on shares of Teleflex in a report on Wednesday, June 24th. Finally, Raymond James Financial reiterated an “outperform” rating and set a $150.00 price objective on shares of Teleflex in a report on Friday, May 8th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus price target of $147.44.

Teleflex Trading Up 2.9%

NYSE TFX opened at $134.16 on Wednesday. The stock has a market capitalization of $5.94 billion, a P/E ratio of -5.88, a P/E/G ratio of 0.97 and a beta of 0.82. The business has a 50 day simple moving average of $129.72 and a 200 day simple moving average of $119.99. The company has a debt-to-equity ratio of 0.82, a current ratio of 2.55 and a quick ratio of 2.03. Teleflex has a one year low of $100.18 and a one year high of $139.67.

Teleflex (NYSE:TFX) last issued its quarterly earnings results on Thursday, May 7th. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.21 by $0.18. The firm had revenue of $548.30 million for the quarter, compared to analyst estimates of $536.91 million. Teleflex had a positive return on equity of 13.29% and a negative net margin of 35.88%.The company’s revenue was up 32.3% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.44 earnings per share. Teleflex has set its FY 2026 guidance at 6.250-6.550 EPS. Research analysts expect that Teleflex will post 6.7 earnings per share for the current year.

Teleflex Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, June 30th. Investors of record on Monday, May 25th were given a $0.34 dividend. The ex-dividend date of this dividend was Friday, May 22nd. This represents a $1.36 annualized dividend and a yield of 1.0%. Teleflex’s dividend payout ratio (DPR) is presently -5.96%.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of TFX. Banque Cantonale Vaudoise lifted its stake in shares of Teleflex by 82.5% in the fourth quarter. Banque Cantonale Vaudoise now owns 250 shares of the medical technology company’s stock valued at $31,000 after buying an additional 113 shares in the last quarter. V Square Quantitative Management LLC bought a new stake in shares of Teleflex during the fourth quarter worth about $37,000. UMB Bank n.a. increased its position in shares of Teleflex by 57.1% during the fourth quarter. UMB Bank n.a. now owns 311 shares of the medical technology company’s stock worth $38,000 after acquiring an additional 113 shares in the last quarter. Sound Income Strategies LLC acquired a new stake in shares of Teleflex in the 4th quarter worth about $45,000. Finally, Kestra Advisory Services LLC acquired a new stake in shares of Teleflex in the 4th quarter worth about $45,000. Institutional investors and hedge funds own 95.62% of the company’s stock.

Teleflex Company Profile

Teleflex Incorporated is a diversified global provider of medical technologies, specializing in critical care and surgery. Headquartered in Wayne, Pennsylvania, the company designs, manufactures and distributes devices and solutions used by healthcare professionals in hospital, ambulatory and alternate site settings. Teleflex focuses on delivering products that support complex interventional procedures and improve patient outcomes.

The company’s offerings span several key segments, including Interventional Urology, Respiratory & Anesthesia, Surgical, Cardiac Care, Vascular and Original Equipment Manufacturer (OEM) solutions.